Abstract:Long-term use of levodopa in the treatment of Parkinson's disease can cause motor complications, which seriously impair the patients'motor function, reduce the quality of life, and aggravate the functional disability. Since there has been no effective treatment for motor complications, clarifying the influencing factors and prevention methods are conducive to reducing the risk of incidence and improving the quality of life of the patients. This paper summarizes the types and mechanism of motor complications of Parkinson's disease, the influencing factors ( levodopa dose, onset age, Helicobacter pylori infection and high protein diet ) and preventive measures ( psychological intervention, low protein diet, rehabilitation exercise and drugs ), so as to provide reference for the prevention and control of the disease.
[1] DORSEY E R,CONSTANTINESCU R,THOMPSON J P,et al.Projected number of people with Parkinson disease in the most populous nations,2005 through 2030[J].Neurology,2007,68(5):384-386. [2] 陈彪. 左旋多巴在帕金森病治疗中的地位及进展[J].中国临床神经科学,2017,25(5):546-550. [3] 刘振国,戚辰.帕金森病运动并发症及其治疗策略[J].中华医学杂志,2009,89(35):2516-2519. [4] 刘振国,万赢,张煜.帕金森病运动并发症干预策略与思考[J].中华神经科杂志,2017,50(9):641-645. [5] 龙武,杨期明,蒋柏菊,等.普拉克索治疗帕金森病运动并发症的临床疗效观察[J].国际神经病学神经外科学杂志,2013,40(2):118-122. [6] 陈生弟,蒋天放.应重视帕金森病早期诊断和运动并发症的防治[J].中国现代神经疾病杂志,2013,13(7):551-554. [7] 陈生弟. 帕金森病运动并发症的防治策略[J].中华老年医学杂志,2016,35(4):343-346. [8] 熊念,孙圣刚.帕金森病运动并发症发生机制的研究进展[J].中国现代神经疾病杂志,2013,13(8):656-662. [9] HESS B.Renal stone clinic survey:calcium stone formers'self-declared understanding of and adherence to physician's recommendations[J].Urolithiasis,2017,45(3):363-370. [10] 陈慧敏,李芳菲,郜丽妍,等.帕金森病异动症危险因素及左旋多巴安全剂量的数据驱动分析[J].中华老年心脑血管病杂志,2017,19(8):789-792. [11] FAHN S,OAKES D,SHOULSON I,et al.Levodopa and the progression of Parkinson's disease[J].N Engl J Med,2004,351(24):2498-2508. [12] 葛芳芳,张振馨.小剂量左旋多巴启动治疗早期帕金森病的研究[J].中国临床神经科学,2013,21(2):178-181. [13] LIU Z G.Understanding and treatment of the motor complications of Parkinson's disease[J].J Clin Intern Med,2011,28(12):800-803. [14] 车雁芳,蔡春生,曾明旋,等.帕金森病患者异动症及症状波动发生情况及其影响因素研究[J].实用心脑肺血管病杂志,2016,24(3):23-26. [15] 王琼,韩丁,陈彤,等.帕金森运动并发症的调查分析[J].中华老年心脑血管病杂志,2013,15(4):390-392. [16] KU S,GLASS G A.Age of Parkinson's disease onset as a predictor for the development of dyskinesia[J].Mov Disord,2010,25(9):1177-1182. [17] 肖一峰. 帕金森运动并发症危险因素回顾性研究[D].福州:福建医科大学,2014. [18] 万赢,刘振国.帕金森病运动并发症的防治与思考[J].中国现代神经疾病杂志,2013,13(8):663-666. [19] 蔡春生,车雁芳,曾明旋,等.根除幽门螺杆菌对帕金森病疗效及运动功能的影响[J].广东医科大学学报,2017,35(3):225-227. [20] CAMCI G,OGUZ S.Association between Parkinson's disease and Helicobacter pylori[J].J Clin Neurol,2016,12(2):147-150. [21] BLAECHER C,SMET A,FLAHOU B,et al.Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients[J].Aliment Pharmacol Ther,2013,38(6):1347-1353. [22] 林菲菲,黄建平,朱文宗,等.幽门螺旋杆菌感染对帕金森病的影响[J].中国临床神经科学,2016,24(5):562-567. [23] 刘欣,刘娜,娄凡,等.幽门螺杆菌感染对帕金森病临床症状的影响[J].卒中与神经疾病,2018,25(2):206-209. [24] 张超,叶军强,李勇昂,等.Hp感染对帕金森病患者运动水平的影响研究[J].中华医院感染学杂志,2017,27(5):1149-1152. [25] 王璐茜,王涛.重视帕金森病的蛋白质饮食管理[J].实用老年医学,2015,29(12):983-985. [26] 刘宋云,熊念,王涛.与帕金森病预防和治疗相关的饮食研究[J].中华神经科杂志,2013,46(10):63-66. [27] 韩明,刘保群.低蛋白饮食对帕金森病患者多巴制剂治疗的影响[J].临床神经病学杂志,2010,23(5):383. [28] 韩炜,张小青,郭艳丹,等.帕金森病的防治与护理进展[J].解放军预防医学杂志,2015,33(1):100-102. [29] 李天凤. 老年抑郁症患者的心理护理研究[C]//全国第六次护理专业学术会议,2018. [30] 王大力,孙正芹,敦昌平,等.帕金森病焦虑与运动并发症关系的研究[J].临床神经病学杂志,2017,30(5):337-340. [31] 韩秀丽,胡雪玲,张婉萍,等.积极心理护理干预对帕金森病合并抑郁和认知功能障碍患者的临床效果[J].国际精神病学杂志,2016,43(6):1141-1144. [32] 牛咏玲. 优质护理缓解老年帕金森病病人抑郁情绪的效果分析[J].护理研究,2019,33(10):1796-1798. [33] 张亚普,尹安春,姜迎君.帕金森病病人的饮食及其相关并发症护理的研究进展[J].护理研究,2016,30(9):3085-3087. [34] 范怀敏,孟德秀.低蛋白饮食对美多巴治疗帕金森病患者疗效及日常生活能力的影响[J].临床合理用药,2019,12(6):39-40. [35] 曲晓丽,苗睿.老年帕金森病患者的饮食及康复护理要点[J].中国现代药物应用,2019,13(7):225-227. [36] 邵明. 帕金森病的康复锻炼[J].中国实用内科杂志,2019,39(9):758-761. [37] 关红玲. 帕金森病患者的康复护理效果探析[J].中国卫生标准管理,2018,8(13):164-166. [38] 刘晓蕾,万志荣,商梦晴,等.健身气功锻炼对帕金森病患者的疗效观察[J].中国神经免疫学和神经病学杂志,2017,24(1):34-37. [39] 宋彩平,朱肖鸿.康复锻炼结合推拿治疗帕金森病30例疗效观察[J].浙江中医杂志,2013,48(2):102. [40] CHONDROGIORGI M,TATSIONI A,REICHMANN H,et al.Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia:a meta-analysis of levodopa-controlled trials[J].Eur J Neural,2014,21(3):433-440. [41] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第三版)[J].中华神经科杂志,2014,47(6):428-433. [42] Parkinson Study Group CALM Cohort Investigators.Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease[J].Arch Neurol,2009,66(5):563-570. [43] 龙武,杨期明,蒋柏菊,等.普拉克索治疗帕金森病运动并发症的临床疗效观察[J].国际神经病学神经外科学杂志,2013,40(2):118-122. [44] 肖桂荣,孙新芳,吴承龙,等.普拉克索治疗帕金森病晚期运动并发症及抑郁的临床研究[J].中国神经免疫学和神经病学杂志,2014,21(3):221-222. [45] WIRDEFELDT K,ODIN P,NYHOLM D.Levodopa-carbidopa intestinal gel in patients with Parkinson's disease:a systematic review[J].CNS Drugs,2016,30(4):381-404. [46] NYHOLM D.Duodopa® treatment for advanced Parkinson's disease:a review of efficacy and safety[J].Parkinsonism Relat Disord,2012,18(7):916-929.